OncoTAb to Highlight a Tumor Specific Marker to Enable Earlier Detection of Breast Cancer in Women with Dense Breasts at 2015 SABCS

Share Article

OncoTAb, Inc., a University of North Carolina at Charlotte (UNCC) spin-out company, announced it will present scientific data highlighting a non-invasive blood test to aid in the early detection of breast cancer in women with dense breast tissue.

OncoTab

“We have been able to use this novel, patented antibody to personalize the blood serum marker levels and build an early detection strategy around it for women with dense breast tissue."

OncoTAb, Inc., a University of North Carolina at Charlotte (UNCC) spin-out company, announced it will present scientific data highlighting a non-invasive blood test to aid in the early detection of breast cancer in women with dense breast tissue. The technology utilizes a monoclonal antibody that is specific to all major breast cancer subtypes, including triple negative breast cancer (TNBC). The presentation, “A monoclonal antibody with exceptional specificity across major breast cancer subtypes,” will take place on Friday, Dec. 11 at the 2015 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.

“The data, which includes results from 486 patient samples, demonstrates that this monoclonal antibody recognizes a tumor specific marker in the serum and tissue, regardless of breast subtypes or breast tissue density,” quotes Pinku Mukherjee, OncoTAb Co-founder & Chief Science Officer, and Mayo Clinic Alumna. “The data clearly demonstrates that this antibody can be used to target tumors in vivo with promising imaging and therapeutic applications, including the development of Chimeric Antigen Receptor (CAR) engineered T-cells for TNBC.” she added.

“We have been able to use this novel, patented antibody to personalize the blood serum marker levels and build an early detection strategy around it for women with dense breast tissue,” said OncoTAb CEO Rahul Puri. “The Agkura™ Personalized Score increases with disease progression and will be available in 2016 as a non-invasive and affordable blood test supplemental to mammography. This early detection strategy has received overwhelming support from clinicians, breast density advocates and women concerned about their high tissue density and low mammography sensitivity.”

Logistics of the featured presentation at SABCS are below. Follow OncoTAb on Twitter @OncoTab.

Title: A monoclonal antibody with exceptional specificity across major breast cancer subtypes. Date: Friday, Dec. 11, 2015: 7:30 to 9:00 a.m. CT. Poster: P4-09-16

This press release is neither an offer to sell nor the solicitation of an offer to buy shares or any other security in any jurisdiction.

About OncoTAb, Inc.

OncoTAb (http://www.oncotab.com) is a University of North Carolina at Charlotte (UNCC) spin-out company that has a patent-protected technology. Its applications span the life cycle of cancer patients, from detecting and locating cancer to treatment and monitoring for recurrence. The company is gearing up to launch its blood test to aid in the early detection of breast cancer in women with dense breast tissue. OncoTAb is in early stages of developing therapeutic applications, including development of Chimeric Antigen Receptor (CAR) engineered T-cells for Triple Negative Breast Cancer. The company is seeking to partner/license its technology for the development of an imaging application to detect cancer in women with dense breast tissue.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Benjamin Carter